S&P 500

5.948,71

0,53%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
Reino Unido
LSE
Aim Immunotech Inc (0A4Y)
Aim Immunotech Inc (0A4Y) Notícias

0A4Y

Aim Immunotech (0A4Y)

Aim Immunotech Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0A4Y

1

Data	Hora	Fonte	Título	Código	Companhia
19/09/2024	09:00	UK Regulatory	AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc
09/05/2024	09:50	UK Regulatory	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	LSE:0A4Y	Aim Immunotech Inc
06/05/2024	09:30	UK Regulatory	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	LSE:0A4Y	Aim Immunotech Inc
29/04/2024	09:55	UK Regulatory	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc
10/04/2024	09:21	UK Regulatory	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	LSE:0A4Y	Aim Immunotech Inc
02/04/2024	08:30	UK Regulatory	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	LSE:0A4Y	Aim Immunotech Inc
26/03/2024	10:05	UK Regulatory	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	LSE:0A4Y	Aim Immunotech Inc
25/03/2024	10:05	UK Regulatory	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	LSE:0A4Y	Aim Immunotech Inc
07/03/2024	10:45	UK Regulatory	AIM ImmunoTech Announces Launch of CEO Corner Platform	LSE:0A4Y	Aim Immunotech Inc
29/02/2024	10:45	UK Regulatory	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update	LSE:0A4Y	Aim Immunotech Inc
14/02/2024	10:55	UK Regulatory	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer	LSE:0A4Y	Aim Immunotech Inc